Clinical Trials
Recurrence prevention in lone paroxysmal atrial fibrillation is better with amiodarone combinations
Published in Clinical Trials Week, October 16th, 2006
According to investigators from People's Republic of China, "The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF."
Y.H. Yin and colleagues at Chongqing University explained, "One-hundred and seventy-seven patients with lone paroxysmal AF were randomly assigned to three treatment groups: group 1 received low-dose...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2006-10-16)
More Articles from Clinical Trials Week
- Cardiology
Women with atrial fibrillation were more prone to anticoagulant-related bleeding than men - Diabetes Therapy
Rosiglitazone is effective and well tolerated in therapeutic regimens in type 2 diabetes - Lymphoma
Lymphoma patient survival was better with high-dose methylprednisolone versus whole-brain radiotherapy - Allergy & Immunology
Cytos Biotechnology's CYT003-QbG10 achieves efficacy in phase IIa pilot study - Alzheimer Disease
Medivation reports phase 2 trial of Alzheimer drug meets all five efficacy endpoints - Alzheimer Disease
Roskamp Institute announces launch of clinical study on Alzheimer treatment - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
